米非司酮治疗子宫肌瘤的临床效果分析

刘亚萍

（宝鸡市陈仓医院妇产科，陕西 宝鸡，721300）

浏览次数：189次 下载次数：343次

摘要：

目的 探讨米非司酮治疗子宫肌瘤的临床效果。方法 选取2014年1月至2015年1月于本院就诊的52例子宫肌瘤患 者，所有患者在月经第1~3 天，每晚睡前口服米非司酮10mg，连续治疗3个月，对比分析治疗前、后子宫及肌瘤的体积，测定治疗前、后的雌激素（E2）、雄激素（T）、泌乳素（PRL）、卵泡刺激素（FSH）、孕酮（P）及黄体生成素（LH）的水平，监测治疗后的血、尿常规及肝肾功能指标。结果 治疗后患者子宫及肌瘤的体积均较治疗前显著缩小（分别缩小26.84%和45.85%）（P<0.05）；血清FSH、LH、P、E2 水平较治疗前显著下降（P<0.05），T 和PRL 水平变化不明显（P>0.05）；治疗后，血、尿常规及肝功能检查均正常。结论 米非司酮治疗子宫肌瘤疗效确切，副反应小，值得临床推广应用。

关键词：米非司酮；子宫肌瘤；雌激素

中图分类号：R737.33文献标志码：A文章编号：2096-1413(2017)13-0042-02

Clinical effect of mifepristone in treatment of uterine leiomyoma
LIU Ya-ping
(Department of Obstetrics and Gynecology, Chencang Hospital, Baoji 721300, China)

ABSTRACT: Objective To study the clinical effect of mifepristone in the treatment of uterine leiomyoma. Methods Fifty-two cases of patients with uterine leiomyoma in our hospital from January 2014 to January 2015 were selected. All the patients received 10 mg mifepristone daily for 90 days beginning on the first 3 days of menstrual cycle. The uterine volume and leiomyoma volume, the serum estrogen (E2), Testosterone (T), prolaction (PRL), follicle-stimulating hormone(FSH), progesterone (P), luteinizing hormone (LH) were detected after the treatment; the blood, urine routine test and liver, renal function were monitored after the treatment. Results After treatment, the uterine volume and leiomyoma volume were significantly decreased (26.84% and 45.85% respectively) (P<0.05); serum FSH, LH, P, E2 at the end of treatment were significantly less than those before the treatment (P<0.05), whereas T and PRL has no significant difference (P>0.05). There was no abnormity in blood and urine routine test and liver and renal function. Conclusion Mifepristone is a safe and effective drug on uterine leiomyoma, with low adverse reaction, and it can be used widely in clinic.
KEYWORDS: mifepristone; uterine leiomyoma; estrogen

参考文献：
[1] BUTTAM VCJ,REITER RC.Uterine leiomyomata: etiology,symptomatology and management[J].Fertil Steril,2013,99(1):23-28.
[2] VOLLENHOVEN BJ,LAWRENCE AS,HEALY DL.Uterine fibroids: a clinical review[J].Br J Obstet Gynecol,1990,97(4):285.
[3] REIN MS,BARBIERI RL,FRIEDMAN AJ.Progesterone: a critical role in the pathogenesis of uterine myomas[J].Am J Obstet Gynecol,1995, 172(1Pt1):14.
[4] MURPHY AA,KETTEL LM,MORALES AJ,et al.Regression of uterine lriomyoma in response to antiprogestin mifepristone [J].J Clin Endocrinol Metab,1993,76(2):513-517.
[5] 赵维红,郭明霞,孟志新.等.甲氨喋呤联合米非司酮治疗异位妊娠疗效观察[J].中国现代医生,2007,45(9):22-23.
[6] 屠铮,魏丽惠,王建六,等.孕激素受体亚型在子宫肌瘤组织中的表达[J].中华妇产科杂志,2000,35(12):740.
[7] 廖爱华.米非司酮的作用机理及临床应用[J].实用妇产科杂志,2014,9(1):15-16.
[8] 王惠群,靳加玉.米非司酮对子宫肌瘤及子宫肌层组织雌、孕激素受体的影响[J].中华妇产科杂志,2000,35(2):79.
[9] 詹美色,翁如林,刘瑞爱.米非司酮治疗子宫肌瘤的疗效观察[J].中国妇幼保健,2006,21(13):1787-1788.
[10] 钟惠芳,胡象莲.米非司酮治疗子宫肌瘤的效果观察[J].实用妇产科杂志,1997,20(5):303-304.
[11] 唐福星,王自能,刘惠敏,等.米非司酮对子宫肌瘤组织超微结构的影响[J].中华妇产科杂志,2000,35(4):242.
[12] 汤春生,董建春.米非司酮治疗子宫肌瘤的作用机制及其临床评价[J].中国实用妇科与产科杂志,2001,17(3):137.
[13] 王莉莉,奚其葵,乌毓明.国内外米非司酮的应用及探索[J].实用妇产科杂志,1997,3(2):72.
[14] 喇端端,吴步初,季晓琼,等.米非司酮对子宫肌瘤超微结构的影响[J].中国实用妇科与产科杂志,2003,19(2):96.
[15] 吴际,程云英.子宫肌瘤组织雌孕激素受体及细胞增殖相关抗原与激素抗体关系探讨[J].中华妇产科杂志,2015,50(10):62-63.
[16] REINSCH RC,MURPHY AA,MORALES AJ,et al.The effects of RU486 and leuprolide acetate on uterine artery blood flow in the fibroid uterue: a prospective, randomized study[J].Am J Obstet Gynecol,1994,170 (6):318-323.